CBIOCrescent Biopharma, Inc.

$345M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10,000-86.7% YoY

Gross Profit

$10,000100.0% margin

Operating Income

-$39M-392752.9% margin

Net Income

-$37M-368994.2% margin

EPS (Diluted)

$-0.58

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$35M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$45M

Total Liabilities

$7M

Stockholders' Equity

$38M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10,000	$75,000	-86.7%
Gross Profit	$10,000	$75,000	-86.7%
Operating Income	-$39M	-$47M	+17.1%
Net Income	-$37M	-$47M	+21.0%

CBIO FY 2023 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena